Class III is the highest-risk NMPA medical device class in China. National review by the Center for Medical Device Evaluation (CMDE) is the default gate for implants, cardiac devices, orthopedic hardware, and other life-sustaining or implantable technology. For portfolio sequencing, Class III timelines — not Class II provincial filings — usually set the critical path into public hospitals.
For market size, NHSA VBP, and import-substitution context, use the canonical China Medical Devices Market Report 2026. This guide isolates registration timing and evidence choices.
Why Class III drives China launch sequencing
Class I filings are local and fast; Class II provincial registrations typically clear in about 6–12 months with predicate equivalence. Class III national CMDE review commonly spans 18–36 months. Launch calendars that treat “China registration” as a single average therefore mis-sequence multi-SKU portfolios: a Class II accessory may be tender-ready years before a Class III implant in the same therapy franchise.
CMDE pathway and clinical evaluation options
Typical Class III workstreams include pre-submission communication with CMDE, technical file preparation in Chinese, clinical evaluation strategy selection, and post-approval vigilance via a Resident Agent for imported products. Clinical evaluation options include:
- A clinical trial conducted in China
- Overseas clinical data with supplementary Chinese bridging evidence
- Literature and equivalence for well-established device types already represented on the Chinese market
Imported manufacturers without a Chinese legal entity must appoint a Resident Agent (代理人) who holds regulatory responsibility for registration maintenance, adverse-event reporting, and correspondence with NMPA/CMDE.
Innovative device priority review
The Special Review Procedure for Innovative Medical Devices (创新医疗器械特别审查程序) can compress queue time for applicants with core domestic IP and a clear clinical advantage. Multinationals without China-origin IP should not treat priority review as an import shortcut; standard CMDE timelines plus localization strategy for post-approval tender scoring remain the realistic base case.
Planning benchmarks for 2026 portfolios
Use Class II ≈ 6–12 months and Class III ≈ 18–36 months as planning bands, then overlay NHSA VBP and Grade III hospital procurement — registration alone does not guarantee public-channel volume. Compare China against other APAC pathways via the Japan medical devices market report and India medical devices market report, or start from the healthcare market research hub.
Related: China device VBP rounds explained.





